<SEC-DOCUMENT>0001193125-22-198108.txt : 20220720
<SEC-HEADER>0001193125-22-198108.hdr.sgml : 20220720
<ACCEPTANCE-DATETIME>20220720161014
ACCESSION NUMBER:		0001193125-22-198108
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220720
DATE AS OF CHANGE:		20220720

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celularity Inc
		CENTRAL INDEX KEY:			0001752828
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				831702591
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-258600
		FILM NUMBER:		221094332

	BUSINESS ADDRESS:	
		STREET 1:		170 PARK AVE
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932
		BUSINESS PHONE:		(908) 768-2170

	MAIL ADDRESS:	
		STREET 1:		170 PARK AVE
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GX Acquisition Corp.
		DATE OF NAME CHANGE:	20180912
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d327634d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PROSPECTUS SUPPLEMENT No.&nbsp;7</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>(to Prospectus dated April&nbsp;7, 2022)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-258600</FONT></B></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g327634g0720034306600.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 22,874,999 Shares of Class&nbsp;A Common Stock Issuable Upon Exercise of Warrants </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 129,858,855 Shares of Class&nbsp;A Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 8,499,999 Warrants to Purchase Class&nbsp;A Common Stock </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement supplements the prospectus, dated April&nbsp;7, 2022 (the &#147;Prospectus&#148;), which forms a part of our registration statement
on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (No. <FONT STYLE="white-space:nowrap">333-258600).</FONT> This prospectus supplement is being filed to update and supplement the information in the Prospectus with the information contained in our
Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the Securities and Exchange Commission on July&nbsp;20, 2022 (the &#147;Current Report&#148;). Accordingly, we have attached the Current Report to this prospectus
supplement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Prospectus and this prospectus supplement relate to the issuance by us of an aggregate of up to 22,874,999 shares of our Class&nbsp;A
common stock, $0.0001 par value per share (the &#147;Class&nbsp;A Common Stock&#148;), which consists of (i)&nbsp;the issuance by us and resale of up to 8,499,999 shares of Class&nbsp;A Common Stock that are issuable upon the exercise of (A)
7,000,000 warrants issued in a private placement to GX Sponsor LLC (the &#147;Sponsor&#148;), in connection with the GX IPO and (B) 1,499,999 warrants issued to certain members of the Sponsor as repayment for certain working capital loans made to GX
(the warrants in (A)&nbsp;and (B) collectively, the &#147;Private Placement Warrants&#148;), and (ii)&nbsp;up to 14,375,000 shares of Class&nbsp;A Common Stock that are issuable upon the exercise of 14,375,000 warrants (the &#147;Public
Warrants,&#148; and, together with the Private Placement Warrants, the &#147;Warrants&#148;) issued in the GX IPO. We will receive the proceeds from the exercise of any Warrants for cash. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Prospectus and this prospectus supplement also relates to the offer and sale from time to time by the selling securityholders named in the Prospectus or
their permitted transferees (the &#147;selling securityholders&#148;) of (i)&nbsp;up to 129,858,855 shares of Class&nbsp;A Common Stock consisting of (a)&nbsp;up to 8,340,000 shares of Class&nbsp;A Common Stock issued in a private placement pursuant
to subscription agreements (&#147;Subscription Agreements&#148;) entered into on January&nbsp;8, 2021 (b) up to 2,000,000 shares of Class&nbsp;A Common Stock issued in a private placement pursuant to a subscription agreement entered into on
May&nbsp;5, 2021 with Palantir Technologies Inc. (&#147;Palantir Technologies&#148;), (c) up to 976,943 shares of Class&nbsp;A Common Stock issued in private placements on July&nbsp;21, 2021 to certain advisors of Legacy Celularity and GX,
(d)&nbsp;up to 7,187,500 shares of Class&nbsp;A Common Stock previously held by the Sponsor following a private placement in connection with the initial public offering of GX, (e)&nbsp;up to 8,499,999 shares of Class&nbsp;A Common Stock issuable
upon exercise of the Private Placement Warrants, (f)&nbsp;up to 19,811,204 shares of Class&nbsp;A Common Stock issuable upon exercise of the Converted Legacy Warrants, (g)&nbsp;up to 11,744,882 shares of Class&nbsp;A Common Stock issuable upon
exercise of options and awards and (h)&nbsp;up to 71,298,327 shares of Class&nbsp;A Common Stock pursuant to that certain Registration Rights Agreement (the &#147;Registration Rights Agreement&#148;), dated July&nbsp;16, 2021, between us and certain
selling securityholders granting such holders registration rights with respect to such shares, and (ii)&nbsp;up to 8,499,999 Private Placement Warrants. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Class&nbsp;A Common Stock and Public Warrants are listed on The Nasdaq Stock Market LLC under the symbols &#147;CELU&#148; and &#147;CELUW&#148;,
respectively. On July&nbsp;19, 2022, the last reported sales price of Class&nbsp;A Common Stock was $3.50 per share and the last reported sales price of our Public Warrants was $0.52 per warrant. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement should be read in conjunction with the Prospectus, including any amendments or supplements thereto, which is to be delivered with
this prospectus supplement. This prospectus supplement is qualified by reference to the Prospectus, including any amendments or supplements thereto, except to the extent that the information in this prospectus supplement updates and supersedes the
information contained therein. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the
Prospectus, including any amendments or supplements thereto. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. You should review carefully
the risks and uncertainties described in the section titled &#147;</B><B><I>Risk Factors&#148; beginning on page 15 of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the
accuracy or adequacy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus
supplement dated July&nbsp;20, 2022. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934 </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): July 14, 2022
</B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>CELULARITY INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-38914</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>83-1702591</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>170 Park Ave</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Florham Park, New Jersey</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>07932</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (908) 768-2170 </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report.) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading<BR>Symbol(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Class A Common Stock, $0.0001 par value per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>CELU</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Stock Market LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Warrants, each exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>CELUW</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Stock Market LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Emerging
growth company &#9746; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744; </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;14, 2022, Andrew L. Pecora, M.D., F.A.C.P., President of Celularity
Inc., or Celularity, notified the board of directors of his decision to resign as President effective as of August&nbsp;31, 2022. Dr.&nbsp;Pecora&#146;s decision to&nbsp;resign&nbsp;was not due to any disagreement with Celularity on any matter, or
relating to its operations, policies, or practices. Celularity expects to enter into a consulting agreement with Dr.&nbsp;Pecora whereby Dr.&nbsp;Pecora will continue to assist Celularity during a transition period and also serve as <FONT
STYLE="white-space:nowrap">co-Chair</FONT> of Celularity&#146;s Scientific Advisory Board. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Date: July&nbsp;20, 2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>&nbsp;&nbsp;&nbsp;&nbsp;CELULARITY INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Keary Dunn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Keary Dunn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Legal Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g327634g0720034306600.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g327634g0720034306600.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !@ *$# 2(  A$! Q$!_\0
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M1#;Q#+MC./RZUEZKIQ\1V]G=6TP6(IO E4C(/(/3\#[&A>8'1>8O]X45Q_\
MPA-U_P!!FX_7_&BKM'N!B?#<6++JAOA$=:^UO]J\X#>![9[=:Z7PZOAD:GJO
M]@F$7'FC[8(B<;OY?E3M8\"Z#KEW]KNK5A<$8:2&0H6'OCK6GI&AZ;H-D+33
MK5((<Y(7JQ]2>I-$IJ3N,\]U;^T$^*MP8I;"*X:S06C:@I*%>XCQ_%GK5A+#
M4Y_'.DW-[J6B1WT&XF*TW"66+^('U%=OK7A[2]?@6+4K-)]ARC$D,OT(Y%5]
M&\):+H$K2V%DJ3,,&5F+/CTR>U'.K!?0H?$G_D0-5'J@_P#0A6_I'_('L?\
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9)D<JA/RK_7\:[0<"G-J]D,/QHI:*D1__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
